)
Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, today announced the USFDA acceptance of The Investigational New Drug (IND) filing for a novel molecule targeting prostate cancer.
This molecule will now progress towards the next phase of development and is anticipated to go into clinical trials by late 2013, a company statement said here.
"We are elated with this successful outcome, which is the result of excellent collaboration between the scientists at Endo and Jubilant Biosys. Being at the forefront of pharmaceutical, life sciences and healthcare innovation, Jubilant pursues its goal to enable affordable healthcare to patients worldwide," President, Global Drug Discovery Services, Jubilant Life Sciences SubirKumar Basak said.
The multi-target oncology collaboration between Jubilant and Endo began four years ago, and is focused on developing best-in-class, differentiated therapies that address the unmet needs of cancer patients worldwide. The collaboration has delivered on multiple milestones across the discovery continuum.
